- Trial phase
- Pivotal Study (CGUARDIANS III IDE)
- Time to market
- The CGUARDIANS III pivotal study began enrolling in June 2026 with no disclosed completion date. The company targets a U.S. commercial launch in 2027 if the study succeeds and FDA approval follows, but this timeline is aspirational and subject to clinical results and regulatory review.
- Why 4/10
- SwitchGuard has no hard dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The CGUARDIANS III pivotal study began enrolling in June 2026 but no completion or data-readout date has been disclosed. The company targets a U.S. commercial launch in 2027 if approved, which is aspirational. ImpactScore is set to 4 (default) because the defining binary events are too distant to drive a near-term share-price move for this specific asset.
SwitchGuard is an early-stage pipeline asset with no hard dated catalyst in the next 12 months. The CGUARDIANS III pivotal study began enrolling in June 2026; watch for enrollment completion updates or interim data announcements, but no timeline has been disclosed. The stock's near-term moves will be driven by the just-approved CGuard Prime TCAR commercial launch and the company's ability to execute after the recent delivery-system recall and dilutive $37.5M offering.
Price Chart
Executive Summary
SwitchGuard is a neuroprotection shunt system being developed by InspireMD (Nasdaq: NSPR) for use during Transcarotid Artery Revascularization (TCAR) procedures to prevent stroke by filtering debris from blood flow. It is in the CGUARDIANS III pivotal study, which received FDA IDE approval in May 2026 and enrolled its first patient in June 2026. The company targets a U.S. commercial launch in 2027 if approved. SwitchGuard faces established competition from Silk Road Medical's ENROUTE system, which is already on the market. For InspireMD, the more immediate value driver is the just-approved (Nov 12, 2026) CGuard Prime TCAR indication, which doubles the U.S. addressable market for its stent platform. The stock has been under pressure from a recent delivery-system recall, withdrawn 2026 guidance, and a dilutive $37.5M public offering priced on Nov 13, 2026.
How It Works
SwitchGuard is a neuroprotection system (a shunt with blood flow indicators) used during Transcarotid Artery Revascularization (TCAR), a minimally invasive procedure to open blocked carotid arteries in the neck. During TCAR, the surgeon makes a small incision in the neck and inserts a tube directly into the carotid artery. The SwitchGuard system shunts blood flow away from the brain during the procedure and filters it to catch any debris (emboli) that could break loose, preventing it from traveling to the brain and causing a stroke. It is designed to work alongside InspireMD's CGuard Prime carotid stent system.
Trial Status
The CGUARDIANS III pivotal study received FDA Investigational Device Exemption (IDE) approval in May 2026, and the first patient was enrolled in June 2026. The study evaluates the safety and efficacy of the SwitchGuard Neuro Protection System for use in TCAR procedures alongside the CGuard Prime 80 cm stent platform. No enrollment completion or data readout date has been disclosed.
The Two-Sided Case
Upcoming Catalysts
- CGUARDIANS III pivotal study enrollment completion update (no date disclosed)
- Potential interim or topline data from CGUARDIANS III (no date disclosed)
- Planned PMA supplement submission for enhanced CGuard Prime for CAS procedures (targeting December 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
InspireMD, Inc. 424B5 NSPR ·Originating report